Cellular and Humoral Immunotherapy in Children, Adolescents and Young Adults With Non-Hodgkin Lymphoma

Authors

Yaya Chu, Department of Pediatrics, New York Medical College, Valhalla, NY, USA.Follow
Aliza Gardenswartz, Department of Pediatrics, New York Medical College, Valhalla, NY, USA.Follow
Caroline Diorio, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Lianna J. Marks, Division of Pediatric Hematology and Oncology, Stanford University School of Medicine, Palo Alto, CA, USA.
Eric Lowe, Division of Pediatric Hematology-Oncology, Children's Hospital of the Kings Daughter, Norfolk, VA, USA.
David T. Teachey, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Mitchell S. Cairo, Department of Pediatrics, New York Medical College, Valhalla, NY, USA; Department of Epidemiology and Community Health, New York Medical College, Valhalla, NY, USA; Department of Medicine, New York Medical College, Valhalla, NY, USA; Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, USA; Department of Cell Biology, New York Medical College, Valhalla, NY, USA; Department of Anatomy, New York Medical College, Valhalla, NY, USA. Electronic address: mitchell_cairo@nymc.edu.Follow

Author Type(s)

Faculty

DOI

10.1016/j.beha.2023.101442

Journal Title

Best Practice & Research. Clinical Haematology

First Page

101442

Document Type

Article

Publication Date

3-1-2023

Department

Pediatrics

Abstract

The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poor-risk population. CD19, CD20, CD22, CD79a, CD38, CD30, LMP1 and LMP2 are attractive targets for immunotherapy in CAYA patients with R/R NHL. Novel anti-CD20 monoclonal antibodies, anti-CD38 monoclonal antibody, antibody drug conjugates and T and natural killer (NK)-cell bispecific and trispecific engagers are being investigated in the R/R setting and are changing the landscape of NHL therapy. A variety of cellular immunotherapies such as viral activated cytotoxic T-lymphocyte, chimeric antigen receptor (CAR) T-cells, NK and CAR NK-cells have been investigated and provide alternative options for CAYA patients with R/R NHL. Here, we provide an update and clinical practice guidance of utilizing these cellular and humoral immunotherapies in CAYA patients with R/R NHL.

Recommended Citation

Chu, Y., Gardenswartz, A., Diorio, C., Marks, L. J., Lowe, E., Teachey, D. T., & Cairo, M. S. (2023). Cellular and Humoral Immunotherapy in Children, Adolescents and Young Adults With Non-Hodgkin Lymphoma. Best Practice & Research. Clinical Haematology, 36 (1), 101442. https://doi.org/10.1016/j.beha.2023.101442